KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

HCA Healthcare (HCA) EBITDA (2016 - 2025)

HCA Healthcare (HCA) has disclosed EBITDA for 16 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 165.71% to $3.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 billion, a 23.02% increase, with the full-year FY2025 number at $5.6 billion, up 9.62% from a year prior.
  • EBITDA was $3.1 billion for Q4 2025 at HCA Healthcare, up from -$3.8 billion in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.1 billion in Q4 2025 to a low of -$4.7 billion in Q4 2024.
  • A 5-year average of $859.7 million and a median of $1.5 billion in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 197.22% in 2021, then tumbled 402.4% in 2025.
  • HCA Healthcare's EBITDA stood at $2.1 billion in 2021, then soared by 31.29% to $2.7 billion in 2022, then dropped by 29.88% to $1.9 billion in 2023, then crashed by 345.15% to -$4.7 billion in 2024, then surged by 165.71% to $3.1 billion in 2025.
  • Per Business Quant, the three most recent readings for HCA's EBITDA are $3.1 billion (Q4 2025), -$3.8 billion (Q3 2025), and -$429.0 million (Q2 2025).